BIG Time for Baby has met its target accrual, enrolling 518 patients
APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen
Several oral presentations and posters related to BIG trials and research collaborations will be presented over the course of these four day
BIG against breast hosted an emotional dinner experience on 14 November
Prof. Cameron, who succeeds BIG co-Founder Prof. Piccart, began his term on 8 November 2019.
On 29 October, the EORTC and BIG organised a public educational session
2nd edition dinner and dance party
Researchers confirm the poor quality of care for men affected by breast cancer and urge for a clinical trial
This year BIG is celebrating its 20th anniversary. What better time than the month of October to spread our message of hope and progress?
The societal impact of this academic study on breast cancer could be substantial
For many years, radiotherapy has been an integral part of treatment for early stage and advanced breast cancer.
Gone are the days when 80-90% of women with breast cancer had a mastectomy
Anti-HER2 therapy is one of the biggest success stories in modern cancer treatment – for metastatic and early stage HER2+ breast cancer
No longer a single disease, but many
On the occasion of the 20th anniversary of BIG, Professor Martine Piccart, gathered experts and supporters to discuss the state of breast c
On Friday 27 September, during the opening ceremony of the ESMO conference, Dr Angelo Di Leo will be honoured with the ESMO Lifetime Achieve
BIG Annual Report 2018: Spreading hope – advancing breast cancer research
MoveforBIG.org Launch party & concert
Last May, BIG and the NABCG held their annual meeting in Chicago, USA, prior to ASCO 2019.
"BIG Time for Baby" continues to advance thanks to the generous support of donors around the globe
For the last 20 years, BIG has been dedicated to developing and conducting major international clinical trials and research programmes to fi
Over one hundred participants ran for BIG against breast cancer!
This advanced form of the disease, responsible for 90% of breast cancer deaths, is more difficult to treat and remains incurable.
Professor Jonas Bergh, BIG official representative for the Swedish Breast Cancer Group (SweBCG), has been awarded with the first ESMO Breast
AURORA Europe and US are two of the most ambitious programmes ever carried out to improve understanding of metastatic breast cancer.
“The Ki67 programme was a truly remarkable and practice-changing development, and it undoubtedly required the kind of international collab
For the 1% of patients with breast cancer who are male, the International Male Breast Cancer Programme (IMBCP) is a key initiative to gain a
For many young women undergoing hormone treatment for endocrine-responsive early breast cancer, the question of if and when they can stop th
The NABCG is a network of US and Canadian researchgroups supported by the US National Cancer Institute (NCI), with major funding from the BC
The BIG-NABCG collaboration: shared goals and shared successes in breast cancer research
On Friday 23 November 2018, the first BIG-East Asia workshop for young investigators took place in Singapore
As BIG is celebrating its 20th anniversary this year, there’s no better time than now to spread our message of hope and progress.
Dr Martine Piccart was honoured with the KNAW Bob Pinedo Cancer Care award
This 11 October, more than 250 people dressed in their very finest, with a touch of pink, joined the dinner and dance to benefit BIG...
On 4 October, BIG against breast cancer has organised its 6th annual gala dinner at Cercle de Lorraine in Brussels.
Fighting breast cancer around the globe: South Asia - India & Pakistan
Call opened for Residual Biological Material
Call opened for access to Study Data
In March 2019, the 16th edition of the St.Gallen International Breast Cancer Conference will take place in Vienna, Austria. BIG had the grea
BIG Time for Baby is making BIG progress: already 262 women enrolled and 32 healthy babies born, a milestone!
Thanks to the support and hard work of BIG’s 59 member groups, breast cancer research made significant progress again in the past year.
Following BIG’s General Assembly (GA), we are very happy to announce the outcome of the BIG Executive Board (EB) elections.
Ovarian Suppression Reduces Recurrence and Can Improve Survival in Young Breast Cancer Patients
Following BIG’s General Assembly we are very happy to announce the outcome of the BIG Executive Board elections
Several abstracts with updates or follow-on analyses from BIG trials were selected for presentation at the upcoming ASCO Annual Meeting.
On 6 April 2018 leading cancer experts from East Asia were invited together with BIG representatives to the Asian Breast Cancer Networking b
"The prize is a wonderful recognition for the dedication and work of our teams at BIG and at the Jules Bordet Institute" says Prof. Piccart.
Fighting breast cancer around the globe: the Middle East
Prof Robert Mansel, Chair of EBCC-11, calls for men to be included in clinical trials to improve treatments for breast cancer.
Every year on 8 March, women are put in the forefront thanks to International Women’s Day. This year, gender parity is the central theme o
Raising awareness about the POSITIVE study, an international academic effort to better understand the correlation between pregnancy and the
Researchers confirm the poor quality of care for men affected by breast cancer and urge for a clinical trial.
SOLTI launches a call for its 2018 Scientific Talent Programme
Access to MINDACT data and residual material
Updated results of the SOFT and TEXT trials
Extended intermittent letrozole not better than continuous use in SOLE study, but temporary treatment breaks may be safe for some patients.
The primary results of PANACEA (BIG 4-13) presented at the San Antonio Breast Cancer Symposium
Let us welcome and introduce you to our newest team members at BIG HQ
40% of women with breast cancer live in Asia.
During the General Assembly held last June in Chicago, four new academic cancer research groups joined BIG.
ESMO 2017 – Letrozole combined with taselisib shows better outcome for postmenopausal women with early stage breast cancer
Biological characteristics play a significant role in determining the aggressiveness of a tumour
Breast cancer research situation in East Asia: what does it look like?
Following the APHINITY Translational Advisory Committee (TAC) and Steering Committee (SC) meetings and the public presentation of the primar
Translational Research Proposals Call opened for Residual Biological Material
The Breast International Group (BIG) is committed to providing clear and timely information about its research activities, fundraising and f
BIG is pleased to announce the election of its new Executive Board. It will go into effect from 1 July 2017.
BIG’s Executive Board is expanding from 9 to 15 members
On 4 and 5 June 2017, both the ALTTO and NeoALTTO studies presented updated results at the American Society of Clinical Oncology (ASCO) Annu
On 4 June 2017, the MINDACT study presented the chemotherapy randomisation results at the American Society of Clinical Oncology (ASCO) Annua
Reflecting the global outreach of BIG, whose 56 academic Members Groups represent the largest international network dedicated to breast canc
Phase III study confirms benefit of the Perjeta-based regimen over the current standard of care The study was positive in the overall pop
SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women w
Further to the main trial results that were presented and published in 2005, the final analysis of the HERA study was recently published in
The annual ASCO meeting will be taking place from 2 to 6 June 2017 and will gather over 30,000 oncology professionals from all corners of th
The international and purely academic POSITIVE study has already recruited more than 100 patients from 113 activated hospitals and cancer ce
In early August 2016, the LORELEI study finished its recruitment three months ahead of schedule, enrolling a total of 334 patients from 103
Dr. Giuseppe Curigliano, a member of the Breast International Group (BIG), to receive the “ESO Umberto Veronesi Memorial Award” during 1
Dr. Martine Piccart to receive the “2017 St. Gallen International Breast Cancer Award” on 15 March 2017.
Foundation SONK is honouring Professor Martine Piccart for her extraordinary clinical research contribution in the advancement of early, cur
The latest BIG Research in Focus newsletter is out and explores cancer clinical research in Latin America through the eyes of local and inte
Perjeta plus Herceptin and chemotherapy showed a statistically significant improvement in invasive disease-free survival (iDFS) for people w
In about one month the 15th edition of the St. Gallen International Breast Cancer Conference will take place in Vienna, Austria. Held every
As the Early Registration deadline for the Pre-IMPAKT Training Course rapidly approaches, the European Society for Medical Oncology (ESMO) c
The Breast International Group (BIG) would like to congratulate Professor Laura van ‘t Veer, a world renowned Molecular Biologist, Profess
The 4th of February is World Cancer Day, a global campaign that takes place every year with the primary object of getting as many people as
In collaboration with the European Society of Medical Oncology (ESMO), we are pleased to announce that the Pre-IMPAKT 2017 Training Course w
From October 13th to November 10th 2016, three early-career medical oncologists and one radiation oncologist from Latin American academic re
On the 24 November 2016, The Hotel. Brussels played host to an evening of fine dining and fun. Indeed, the gala-dinner was punctuated by the
IMPAKT 2017 will be hosted by the Breast International Group (BIG) and ESMO, in collaboration with a multidisciplinary alliance of European
This 24 November 2016 will be marked by the 4th Belgian edition of “The Designers’ Christmas Tree” gala and auction held at The Hotel
World renowned oncologist and founder of the European CanCer Organisation, Professor Umberto Veronesi, passed away at the age of 90 in his h
ESMO and BIG invite you to submit your abstract for the IMPAKT 2017 Breast Cancer Conference, taking place in Brussels from 4 May till 6 May
The 4th issue of BIG Research in Focus highlights some challenges and questions raised by the ever-increasing cost of new breast cancer drug
For more than ten years now BIG and the North American Breast Cancer Group (NABCG) have been meeting annually and in topic-specific working
Checkpoint inhibitors make headlines with promising new data in cancer treatment on an almost daily basis, especially in melanoma and lung c
Because of the rarity of male breast cancer, which accounts for less than 1% of all breast cancers diagnosed worldwide and for 1% of all can
Four young oncologists from Latin America arrived this week in Brussels to follow a training programme dedicated to clinical research develo
1 in 3 breast cancer patients will develop metastases. While there is no cure for metastatic breast cancer, some individuals are able to liv
Today a woman’s chance of being diagnosed with breast cancer is still 1 in 8. Of course there has been progress in breast cancer research.
Celebrities are giving their support to the crowdfunding campaign BIG Time for Baby and the action #AllStorks, to fund an important internat
The first results of the MINDACT trial, using the MammaPrint® test, have just been presented and give hope to many women with early-stage b
To co-coincide with International Clinical Trials Day (20 May 2016), Cancer Trials Ireland (formerly known as the All-Ireland Cooperative On
BIG has received a $1 million educational grant from Pfizer Inc. to support academic research in the field of breast cancer.
EORTC (European Organisation for Research and Treatment of Cancer), BIG (Breast International Group), and Agendia are pleased to announce th
BIG and ESMO regret to inform you that the IMPAKT 2016 Breast Cancer Conference, 12-14 May and the pre-IMPAKT Training Course, 11 May in Bru
EORTC, BIG, and Agendia are pleased to announce that the “Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, rand
This 4th issue of the BIG Research in Focus newsletter highlights some challenges and questions raised by the ever-increasing cost of new br
The Breast International Group (BIG) is proud to announce that it has received a $1 million educational grant from Pfizer Inc. to support ac
We look forward to meeting you at IMPAKT 2016 in Brussels on 12-14 May 2016!
More than 500 oncologists and other experts are expected to gather in Brussels from 12 to 14 May 2016 at the 8th IMPAKT Breast Cancer Confer
On 30 November 2015, Dr. Christos Sotiriou received the quinquennial “Prix Scientifique Joseph Maisin” in the category of “Clinical Bi
Amplified benefit of adding denosumab for the treatment of postmenopausal patients with early stage hormone receptor (HR)-positive breast ca
The Breast International Group (BIG) is proud to announce that, on 9 December 2015, its Co-founder and Chair, Dr. Martine Piccart, received
A fabulously festive evening took place in the frame of the 3rd Belgian edition of The Designers’ Christmas Trees gala dinner and auction
The 18th November 2015 marked the opening exhibition of the third Belgian edition of 'The Designers' Christmas Trees' in TheHotel. Brussels.
Abstract submission open and programme available.
Insights from the European Cancer Congress 2015 (Vienna, 25-29 Sept.)
We now understand the uniqueness of each tumour. However, the deeper we dig into tumour heterogeneity, the more complex is our fight against
Meet Kirby, a young Australian woman participating in the BIG Time for Baby study (scientific name: POSITIVE)
Last August the BIG Headquarters hailed the arrival of Dr Nawale Hajjaji, coming on board as Scientific Advisor.
Professor John Forbes, Director of Research at the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG), was recently honored with
Last June Prof. Laura van ’t Veer from the Netherlands Cancer Institute (NKI) and her team received the prestigious European Inventor Awar
The future is here: everyday healthcare is now intertwined with technology at every level.
Launched in 2014, BIG Time for Baby (scientific name: POSITIVE) is an international academic study that represents a unique opportunity for
On Saturday 22 August, one of our close ambassadors invited 40 friends and acquaintances to attend a dinner at the prestigious Gstaad Yacht
Last week results of the international study MA.20 showing the benefit of lymph node radiation in long-term breast cancer control were relea
In 2014 an Operational Working Group was set up to allow BIG member groups and BIG Headquarters (HQ) to discuss ways to work more efficientl
The Iranian Cancer Research Center (ICRC) joined BIG during the organisation’s General Assembly that took place on 31 May 2015. Dr. Sana
In 2014 the BIG network launched AURORA, the largest international research programme based on molecular screening and dedicated to improvin
Since founding BIG in 1999, 15 years have passed. 15 years of collaboration to move breast cancer research forward while reducing duplicatio
Regarding his analysis of PIK3CA mutations’ prognostic relevance in early breast cancer.
The American Society of Clinical Oncology (ASCO) Annual Meeting 2015 took place recently in Chicago, USA.
Since its launch in 2014 the Metastatic Breast Cancer GPS (AURORA) has been activated in 9 hospitals in 4 different countries: Belgium, Luxe
Last Wednesday 22 July the EU Parliament adopted a new Declaration on the Fight against Breast Cancer.
A Written Declaration on the Fight Against Breast Cancer in the European Union co-authored by ten MEPs and backed by EUROPA DONNA – The E
Since its launch in December 2014, the study has been activated in 10 hospitals in 3 different countries: Switzerland, Italy and Australia.
BIG Time for Baby (scientific name: POSITIVE) is a global academic study representing a unique opportunity to allow young women with breast
A few days ago, Dr José Baselga was inaugurated as President of the American Association for Cancer Research (AACR) 2015-2016.
An Australian woman has recently become the first world's patient enrolled in the international clinical trial PANACEA.
On 6-7 May the Pre-IMPAKT training course on breast cancer will be hosted at the SQUARE Meeting Centre, based in the centre of Brussels.
Metastatic Breast Cancer GPS Programme (Scientific Name: AURORA)
A few weeks ago the 14th edition of the St Gallen International Breast Cancer Conference took place in Vienna.
At the last General Assembly of BIG in June 2014, six new research groups joined the organisation, further enlarging its international reach
The IT platform needed to support AURORA sample collection, patient entry, and data work-flow has been significantly refined in the past 6 m
A video was produced to present the tools developed within the INTEGRATE project to potential end-users such as researchers and oncologists.
Member of the BIG Committee of Ambassadors
President of the BIG Committee of Ambassadors
On the "Finely Tuned Radiotherapy" trial
'Taking personalised breast cancer treatment from dream to reality: how can we unleash the potential of biomarker-based clinical trials?'
In 2014 six new research groups joined BIG, further enlarging its international network reach. One of these groups is the Hong Kong Breast O
More than 6 million women are living with breast cancer.
To celebrate the end of our 15th anniversary year, BIG would like to share a look back at "A Year in 15 Moments!"
Title
Name
Firstname
Organisation
Email
Subscribe
Breast International Group
